These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9257533)

  • 21. Design and optimization of sequence-specific hairpin ribozymes.
    Romero-López C; Barroso-delJesus A; Puerta-Fernández E; Berzal-Herranz A
    Methods Mol Biol; 2004; 252():327-38. PubMed ID: 15017061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast.
    Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.
    Rossi JJ; Elkins D; Zaia JA; Sullivan S
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):183-9. PubMed ID: 1540406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR.
    Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
    Dorai T; Olsson CA; Katz AE; Buttyan R
    Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetracycline-regulated expression of hammerhead ribozymes in vivo.
    Bowden ET; Riegel AT
    Methods Mol Biol; 2004; 252():179-94. PubMed ID: 15017049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function.
    Muotri AR; da Veiga Pereira L; dos Reis Vasques L; Menck CF
    Gene; 1999 Sep; 237(2):303-10. PubMed ID: 10521654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes.
    Ohme-Takagi M; Shinshi H; Oda M; Uchimaru T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1990; (22):49-50. PubMed ID: 1714571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific gene suppression by engineered ribozymes in monkey cells.
    Cameron FH; Jennings PA
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9139-43. PubMed ID: 2556702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification and application of self-trimming hairpin ribozymes to targeting a transcribed RNA in vitro.
    Komatsu Y; Shirai M; Ohtsuka E
    J Biochem; 1998 Nov; 124(5):986-91. PubMed ID: 9792923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors.
    Weinberg MS; Ely A; Passman M; Mufamadi SM; Arbuthnot P
    Oligonucleotides; 2007; 17(1):104-12. PubMed ID: 17461767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and expression of chimeric U1/ribozyme transgenes.
    Abounader R; Montgomery R; Dietz H; Laterra J
    Methods Mol Biol; 2004; 252():209-19. PubMed ID: 15017051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of in vivo activities of 5'-connected and 3'-connected cis-acting ribozymes: selection of intracellularly active ribozymes using the gene for dihydrofolate reductase (DHFR) as a selective marker in Escherichia coli.
    Hamada M; Fujita S; Kise H; Jigami Y; Taira K
    J Biochem; 1998 Apr; 123(4):684-92. PubMed ID: 9538262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maxizyme technology.
    Iyo M; Kawasaki H; Taira K
    Methods Mol Biol; 2004; 252():257-65. PubMed ID: 15017055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
    Medina MF; Joshi S
    Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.